An overview of ceftolozane sulfate + tazobactam for treating hospital acquired pneumonia. (12th June 2020)

• Record Type: Journal Article
• Authors: Los-Arcos, Ibai; Burgos, Joaquin; Falcó, Vicenç; Almirante, Benito
• Is Part Of: Expert opinion on pharmacotherapy. Volume 21:Number 9(2020)
• Page Start: 1005
• Page End: 1013
• Publication Date: 2020-06-12
• Subjects: Ceftolozane-tazobactam -- hospital-acquired pneumonia -- ventilator-acquired pneumonia -- multidrug-resistant organisms -- Pseudomonas aeruginosa; Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1080/14656566.2020.1739269
• Languages: English
• ISSNs: 1465-6566

Abstract

ABSTRACT: Introduction: Ceftolozane-tazobactam is a combination of a new cephalosporin, with activity similar to that of ceftazidime, and a known inhibitor of beta-lactamases. This compound shows excellent activity against most gram-negative organisms causative of hospital-acquired pneumonia (HAP) or ventilator-acquired pneumonia (VAP), including extended spectrum beta-lactamase (ESBL)-producing Enterobacterales and multidrug-resistant (MDR) Pseudomonas aeruginosa . Areas covered: This article reviews the spectrum of activity, the main pharmacokinetic and pharmacodynamic characteristics and the clinical efficacy and safety of ceftolozane-tazobactam in the treatment of HAP/VAP in adult patients. Expert opinion: The results of a randomized clinical trial have demonstrated an efficacy and safety profile of ceftolozane-tazobactam similar to that of its comparator for the treatment of patients with HAP/VAP. Several retrospective studies have shown good efficacy of the drug for the treatment of respiratory infections caused by MDR P. aeruginosa . The use of this drug may be incorporated as a new therapeutic option for the treatment of patients with HAP/VAP in a carbapenem-saving setting or as a therapeutic alternative with a better safety profile than other therapeutic options in patients with infections caused by MDR P. aeruginosa .